Aggressive and prolonged treatment of refractory status epilepticus may be justified in patients with cardiac arrest with favorable multimodal prognostic indicators.
There are considerations for treating these seizures as part of the overall goals of palliative care, which include the family’s experience.
The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.
The efficacy was reported to be significantly higher in patients who had taken benzodiazepines.
The investigators concluded that these findings should help to identify targets for intervention to reduce the overall time to treatment in this population.
The investigators hope that the consensus statement helps resolve several clinical questions in cases of pediatric new onset status epilepticus syndromes.
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
Approximately one-third of pediatric patients with refractory convulsive status epilepticus develop neurologic deficits.
Rectal diazepam is currently the only FDA-approved treatment for pediatric status epilepticus.
Brexanolone may help wean patients with super-refractory status epilepticus off of third-line agents.
